星空传媒91传媒制片厂|明星换脸五级片|麻豆传媒映画女演员王茜|麻豆在传媒在线|九九国产|91制片厂在线观看一二区|夜夜草视频|四虎影院在线播放|国产精品亚洲国际在线看|大象传媒国产第一页,麻豆映画传媒有免费的吗,91制片厂安卓,亚洲成年人精选,91你懂得国产,爱豆视传媒短视频免费,免费一级片

One of Akesobio's production workshops.

The 34th China Medicine Economic Information Conference (CMEIC) has been held recently, with the participation of more than 2,000 industry leaders and guests from over 500 pharmaceutical enterprises across China.

Due to its strong innovation strength and fruitful achievements in the biomedical field, Zhongshan-based company Akesobio claimed two awards: "Top Power - Enterprises with Remarkable Achievements in High-quality Development of China's Pharmaceuticals (2022)" and "Top Power - Brands with Remarkable Achievements in High-quality Development of China's Pharmaceuticals (2022)" for its self-developed Cadonilimab? (Cadonilimab Injection), the world's first PD-1/CTLA-4 bi-specific antibody drug approved for marketing.

So far, Akesobio has successfully developed more than 30 innovative drug candidates for oncology, autoimmunity, inflammation, metabolic disease and other major diseases, among which 17 novel drugs are under clinical research.